Q3 Earnings Forecast for TSE:MDP Issued By Raymond James

Medexus Pharmaceuticals Inc. (TSE:MDP) – Research analysts at Raymond James issued their Q3 2025 earnings estimates for Medexus Pharmaceuticals in a report issued on Tuesday, November 19th. Raymond James analyst M. Freeman expects that the company will post earnings per share of $0.01 for the quarter. Raymond James has a “Outperform” rating and a $4.00 price objective on the stock. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share. Raymond James also issued estimates for Medexus Pharmaceuticals’ Q4 2025 earnings at $0.01 EPS, FY2025 earnings at $0.14 EPS, Q1 2026 earnings at $0.22 EPS, Q2 2026 earnings at $0.22 EPS, Q3 2026 earnings at $0.24 EPS, Q4 2026 earnings at $0.24 EPS, FY2026 earnings at $0.92 EPS, FY2027 earnings at $0.90 EPS and FY2028 earnings at $0.89 EPS.

MDP has been the topic of a number of other reports. Leede Financial set a C$8.25 price target on Medexus Pharmaceuticals and gave the company a “speculative buy” rating in a research report on Monday, September 30th. Stifel Nicolaus increased their target price on shares of Medexus Pharmaceuticals from C$3.00 to C$3.50 and gave the stock a “buy” rating in a research report on Thursday, August 22nd. Finally, Stifel Canada raised shares of Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a report on Monday, August 12th. Three equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of C$5.25.

Medexus Pharmaceuticals Trading Up 15.0 %

Shares of MDP opened at C$2.45 on Friday. The stock has a market cap of C$60.10 million, a PE ratio of 49.00 and a beta of 1.96. Medexus Pharmaceuticals has a 1 year low of C$1.44 and a 1 year high of C$3.16. The stock has a 50 day simple moving average of C$2.45 and a 200-day simple moving average of C$2.19.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.